The HDAC2 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa cells, featuring targeted disruption of the HDAC2 gene. This heterogeneous pool harbors diverse loss-of-function mutations introduced by CRISPR/Cas9-mediated gene editing, enabling functional analysis without clonal bias. The polyclonal format retains genotypic variation, closely mimicking the heterogeneity found in tumors and allowing robust interrogation of HDAC2??s roles in chromatin biology and signal transduction.
The HeLa host cell line originates from a human cervical adenocarcinoma and is HPV18-positive, expressing viral oncoproteins E6 and E7 that inactivate p53 and Rb, respectively. This immortalized epithelial line is a mainstay in cancer research, offering rapid growth, straightforward culture, and a well-annotated genome. Its native transcriptional and epigenetic machinery provides a permissive environment for dissecting HDAC2-mediated chromatin remodeling and its consequences on oncogenic phenotypes. HeLa cells are therefore an appropriate model for studying the intersection of viral oncogenesis and epigenetic regulation.
HDAC2 is a class I histone deacetylase that removes acetyl groups from histones H3 and H4, leading to chromatin condensation and transcriptional silencing. It also deacetylates non-histone proteins such as p53, STAT1, and NF-??B, modulating their activity. HDAC2 operates within Sin3, NuRD, and CoREST corepressor complexes through interactions with MTA2, RbAp48, and MBD2. Its expression is driven by transcription factors SP1, MYC, and E2F, and its catalytic activity is inhibited by class I HDAC inhibitors. Through these interactions, HDAC2 regulates genes central to cell cycle progression, apoptosis, and Wnt/??-catenin signaling.
Loss of HDAC2 in HeLa cells disrupts the delicate balance of histone acetylation, particularly at promoters controlled by p53, NF-??B, and ??-catenin target genes, leading to altered gene expression that may counteract HPV-driven immortalization. The polyclonal knockout population preserves cellular heterogeneity, enabling the study of how HDAC2 loss sensitizes cells to apoptotic stimuli or cell cycle arrest, and providing a platform to identify synthetic vulnerabilities exploitable with HDAC inhibitors in cervical adenocarcinoma.
Researchers can employ this model for Western blotting to confirm HDAC2 ablation and monitor histone acetylation, RT-qPCR to assess downstream transcriptional changes, and ChIP-qPCR to profile histone modifications at specific loci. Further applications include cell viability and apoptosis assays (annexin V) to quantify drug responses, alongside flow cytometry for cell cycle distribution. HDAC activity assays and inhibitor sensitivity screening extend utility to epigenetic drug discovery. For additional information, please contact Ascent Research.
